{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:00:12Z","timestamp":1793692812702,"version":"4.5.1"},"reference-count":21,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T00:00:00Z","timestamp":1649289600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81870905"],"award-info":[{"award-number":["81870905"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U20A20358"],"award-info":[{"award-number":["U20A20358"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hangzhou Zhongmei Huadong Pharmaceutical Co,Ltd","award":["no award\/grant number"],"award-info":[{"award-number":["no award\/grant number"]}]},{"name":"Capital\u2019s Funds for Health Improvement and Research","award":["2020-1-2041"],"award-info":[{"award-number":["2020-1-2041"]}]},{"name":"Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences","award":["2019-I2M-5-029"],"award-info":[{"award-number":["2019-I2M-5-029"]}],"id":[{"id":"https:\/\/ror.org\/02drdmm93","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Stroke Vasc Neurol"],"accepted":{"date-parts":[[2022,3,2]]},"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Indobufen can reversibly inhibit platelet aggregation and showed to be effective in the treatment of ischaemic heart and peripheral vascular diseases. However, it is unclear whether indobufen is an alternative antiplatelet agent for treatment of patients with ischaemic stroke.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To test whether indobufen is non-inferior to aspirin in reducing the risk of new stroke at 3 months in patients with moderate to severe ischaemic stroke.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>The Indobufen vs Aspirin in Acute Ischaemic Stroke (INSURE) is a randomised, double-blind, double-dummy, positive drug control, non-inferior multicentre clinical trial conducted in 200 hospitals in China. Participants will be randomised at a 1:1 ratio to receive either 100\u2009mg indofufen two times daily or 100\u2009mg aspirin once daily within 72\u2009hours of the onset of symptoms from day 1 to 3 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study outcomes<\/jats:title>\n                    <jats:p>The primary efficacy outcome is a new stroke (ischaemic or haemorrhagic) within 3 months and the primary safety outcome is a severe or moderate bleeding event within 3 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The INSURE trial will evaluate whether indobufen is non-inferior to aspirin in reducing the risk of new stroke at 3 months in patients with moderate to severe ischaemic stroke.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03871517\">NCT03871517<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/svn-2021-001480","type":"journal-article","created":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T12:51:00Z","timestamp":1649335860000},"page":"e001480","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Indobufen versus aspirin in acute ischaemic stroke (INSURE): rationale and design of a multicentre randomised trial"],"prefix":"10.1136","volume":"7","clinical-trial-number":[{"clinical-trial-number":"nct03871517","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3082-6789","authenticated-orcid":false,"given":"Yuesong","family":"Pan","sequence":"first","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"China National Clinical Research Center for Neurological Diseases (NCRC-ND), Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"China National Clinical Research Center for Neurological Diseases (NCRC-ND), Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2551-9314","authenticated-orcid":false,"given":"Weiqi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"China National Clinical Research Center for Neurological Diseases (NCRC-ND), Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9822-5758","authenticated-orcid":false,"given":"Jing","family":"Jing","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"China National Clinical Research Center for Neurological Diseases (NCRC-ND), Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxi","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"China National Clinical Research Center for Neurological Diseases (NCRC-ND), Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"China National Clinical Research Center for Neurological Diseases (NCRC-ND), Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2912-0714","authenticated-orcid":false,"given":"S Claiborne","family":"Johnston","sequence":"additional","affiliation":[{"name":"Dell Medical School, The University of Texas System, Austin, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip M","family":"Bath","sequence":"additional","affiliation":[{"name":"Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3154-0985","authenticated-orcid":false,"given":"An-Ding","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital of Jinan University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8591-4105","authenticated-orcid":false,"given":"Hao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"China National Clinical Research Center for Neurological Diseases (NCRC-ND), Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"China National Clinical Research Center for Neurological Diseases (NCRC-ND), Beijing, China"},{"name":"Advanced Innovation Center for Human Brain Protection, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"Research Unit of Artificial Intelligence in Cerebrovascular Disease, Chinese Academy of Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,4,7]]},"reference":[{"key":"2025082410403454000_7.5.e001480.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00551-6"},{"key":"2025082410403454000_7.5.e001480.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32203-7"},{"key":"2025082410403454000_7.5.e001480.3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.5853\/jos.2020.03391","article-title":"Residual risk and its risk factors for ischemic stroke with adherence to Guideline-Based secondary stroke prevention","volume":"23","author":"Pan","year":"2021","journal-title":"J Stroke"},{"key":"2025082410403454000_7.5.e001480.4","doi-asserted-by":"publisher","DOI":"10.1161\/strokeaha.120.028992"},{"key":"2025082410403454000_7.5.e001480.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215340"},{"key":"2025082410403454000_7.5.e001480.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800410"},{"key":"2025082410403454000_7.5.e001480.7","doi-asserted-by":"publisher","DOI":"10.1136\/svn-2021-001383"},{"key":"2025082410403454000_7.5.e001480.8","first-page":"e364","article-title":"Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American heart Association\/American stroke association","volume":"2021","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"key":"2025082410403454000_7.5.e001480.9","doi-asserted-by":"publisher","DOI":"10.1136\/svn-2020-000378"},{"key":"2025082410403454000_7.5.e001480.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2011.08.080"},{"key":"2025082410403454000_7.5.e001480.11","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.115.002896"},{"key":"2025082410403454000_7.5.e001480.12","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehz889","article-title":"Aspirin desensitization procedures in aspirin intolerant patients: a neglected topic in the ESC 2019 chronic coronary syndrome guidelines","volume":"41","author":"Bianco","year":"2020","journal-title":"Eur Heart J"},{"key":"2025082410403454000_7.5.e001480.13","first-page":"105","article-title":"Comparison of aspirin and indobufen in healthy volunteers","volume":"27","author":"Lee","year":"2016","journal-title":"Platelets"},{"key":"2025082410403454000_7.5.e001480.14","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00019501-199809040-00007","article-title":"Indobufen compared with aspirin and dipyridamole on graft patency after coronary artery bypass surgery: results of a combined analysis","volume":"9","author":"Cataldo","year":"1998","journal-title":"Coron Artery Dis"},{"key":"2025082410403454000_7.5.e001480.15","doi-asserted-by":"publisher","DOI":"10.1177\/000331979104200102"},{"key":"2025082410403454000_7.5.e001480.16","doi-asserted-by":"crossref","first-page":"94","DOI":"10.23736\/S0026-4725.19.04787-X","article-title":"Management of aspirin intolerance in patients undergoing percutaneous coronary intervention. The role of mono-antiplatelet therapy: a retrospective, multicenter, study","volume":"67","author":"Bianco","year":"2019","journal-title":"Minerva Cardioangiol"},{"key":"2025082410403454000_7.5.e001480.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309023291001"},{"key":"2025082410403454000_7.5.e001480.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30468-8"},{"key":"2025082410403454000_7.5.e001480.19","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3109\/09537104.2012.686072","article-title":"Clopidogrel plus indobufen in acute coronary syndrome patients with hypersensitivity to aspirin undergoing percutaneous coronary intervention","volume":"24","author":"Barill\u00e0","year":"2013","journal-title":"Platelets"},{"key":"2025082410403454000_7.5.e001480.20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.02759.x"},{"key":"2025082410403454000_7.5.e001480.21","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.116.004368"}],"updated-by":[{"DOI":"10.1136\/svn-2021-001480corr1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T00:00:00Z","timestamp":1676937600000}}],"container-title":["Stroke and Vascular Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/svn-2021-001480","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T17:40:45Z","timestamp":1756057245000},"score":1,"resource":{"primary":{"URL":"https:\/\/svn.bmj.com\/lookup\/doi\/10.1136\/svn-2021-001480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,7]]},"references-count":21,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,2,20]]},"published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1136\/svn-2021-001480"],"URL":"https:\/\/doi.org\/10.1136\/svn-2021-001480","relation":{},"ISSN":["2059-8688","2059-8696"],"issn-type":[{"value":"2059-8688","type":"print"},{"value":"2059-8696","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,7]]}}}